Free Trial
NASDAQ:MGTX

MeiraGTx Q2 2024 Earnings Report

MeiraGTx logo
$5.07 -0.29 (-5.41%)
As of 01:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MeiraGTx EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.45
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$0.28 million
Expected Revenue
$16.38 million
Beat/Miss
Missed by -$16.10 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Monday, August 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MeiraGTx's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MeiraGTx Earnings Headlines

FY2025 EPS Estimates for MeiraGTx Lowered by Chardan Capital
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

View MeiraGTx Profile

More Earnings Resources from MarketBeat